Accelerating access to precision oncology trials: risk-benefit framework for local biomarker tests for patient enrollment

Using biomarker test results from a patient’s medical record or testing by a local clinical site can accelerate trial enrollment when compared with using a trial sponsor’s clinical trial assay or candidate companion diagnostic provided by central laboratories. However, doing so may create technical, operational, and regulatory complexities for sponsors. A risk-based framework can inform sponsor decisions and awareness of risks and benefits as interest in using local tests increases.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2026-11-18
DOI
https://doi.org/10.1038/s41698-026-01765-8
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Accelerating access to precision oncology trials: risk-benefit framework for local biomarker tests for patient enrollment

Thomas R. Battersby, Lindee Goh, Simon Patrick Dearden, Barbara A. Zehnbauer et al.
2 links
npj Precision Oncology
Ethics in Clinical Research
article

Accelerating access to precision oncology trials: risk-benefit framework for local biomarker tests for patient enrollment

Thomas R. Battersby, Lindee Goh, Simon Patrick Dearden, Barbara A. Zehnbauer, Scott Donald Patterson, Kelly Smith Oliner, Janet Yikai Jin, Abde M. Abukhdeir, S.E. Wildsmith, Danielle Michelle Townsley, Bowen Cui, Alexander G. Kohlmann, Elizabeth J. Shaughnessy
article en

Abstract

Using biomarker test results from a patient’s medical record or testing by a local clinical site can accelerate trial enrollment when compared with using a trial sponsor’s clinical trial assay or candidate companion diagnostic provided by central laboratories. However, doing so may create technical, operational, and regulatory complexities for sponsors. A risk-based framework can inform sponsor decisions and awareness of risks and benefits as interest in using local tests increases.

npj Precision Oncology
AstraZeneca (United Kingdom) (GB), Amgen (United States) (US), Emory University (US), AstraZeneca (Netherlands) (NL), Precision for Medicine (United States) (US), Gilead Sciences (United States) (US), AstraZeneca (United States) (US)
Amgen, Eli Lilly and Company, AstraZeneca, Gilead Sciences
Good health and well-being
Ethics in Clinical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon